We previously reported that stromal cell-derived factor-1␣ (SDF-1␣, a homing signal for recruiting endothelial progenitor cells (EPC) to areas of neovascularization), is down-regulated in diabetic wounds (Gallagher et al, J Clin Invest. 2007;117:1249 -1259. We now investigate signals whereby mature endothelial cells (EC) and circulating EPC achieve SDF-1␣-mediated EPC homing. Methods: SDF-1␣ in diabetic wounds were therapeutically increased by injection of SDF-1␣-engineered bone marrow-derived fibroblasts versus control cells (N ϭ 48 ͓20, non-obese diabetic (NOD)͔, ͓28, streptozotocin-C57͔). Polymerase chain reaction-array gene expression differences were validated by Western blotting and immunohistochemistry. The role of adhesion molecule(s) in mediating SDF-1␣-induced EPC homing, and wound healing was furthered studied using antagonists in vitro and in vivo. Results: Increasing wound SDF-1␣ via cell-based therapy promotes healing in diabetic mice (ϳ20% increase in healing rates by day 3, P ϭ 0.006). SDF-1␣ increased EC-EPC adhesion and specifically upregulated E-selectin expression in human microvascular EC (2.3-fold increase, P Ͻ 0.01). This effect was also significant in blood vessels of the experimental mice and resulted in increased wound neovascularization. The regulatory effects of SDF-1␣ on EC-EPC adhesion and EPC homing were specifically mediated by E-selectin, as the application of E-selectin antagonists significantly inhibited SDF-1␣-induced EC-EPC adhesion, EPC homing, wound neovascularization, and wound healing. Conclusions: SDF-1␣-engineered cell-based therapy promotes diabetic wound healing in mice by specifically upregulating E-selectin expression in mature EC leading to increase EC-EPC adhesion, EPC homing, and increased wound neovascularization. These findings provide novel insight into the signals underlying the biological effect of SDF-1␣ on EPC homing and point to E-selectin as a new potential target for therapeutic manipulation of EPC trafficking in diabetic wound healing.
R estoring blood flow to the site of injured tissue is a prerequisite for mounting a successful repair response. It is now well established that the sources of endothelial cells (EC), which build newly formed blood vessels come from both pre-existing vessels (angiogenesis) and bone marrow-derived endothelial progenitor cells (EPC) (vasculogenesis). In addition to direct cellular contribution to new vessels, EPC secrete growth factors and cytokines that enhance angiogenesis and other wound-healing processes via paracrine effects. EPC are the key cellular effectors of both reparative and pathologic postnatal neovascularization and play a pivotal role in not only wound healing, but also limb ischemia, 1-3 postmyocardial infarction, 4 -6 endothelialization of vascular grafts, 7, 8 atherosclerosis, 9 retinal and lymphoid organ neovascularization, 10, 11 vascularization during neonatal growth, 12 and tumor growth. 13, 14 The recruitment of EPC from the bone marrow and circulation to sites of neovascularization by the process known as "homing" is subject to regulation by many factors, including chemokines and growth factors. Stromal cell-derived factor (SDF)-1␣ is the predominant chemokine that acts as a potent homing signal for EPC. 15 We have previously demonstrated that the local concentration of SDF-1␣ in diabetic wounds is significantly decreased. Epithelial cells and myofibroblasts appear to be responsible for the down-regulation of SDF-1␣ in diabetic wounds, whereas the exogenous administration of SDF-1␣ to wounds of diabetic mice increase the wound-level EPC recruitment and directly impact wound angiogenesis/vasculogenesis, collagen deposition, and wound closure rates. 16 SDF-1␣ is a chemoattractant that exerts its role through binding with its receptor C-X-C chemokine receptor 4 (CXCR4), which is expressed on the cell surface of EPC 17 and may function as a sensor for circulating EPC cruising through sites of the microvasculature wherein an SDF-1␣ gradient is present. In fact, inhibition of the SDF-1␣/CXCR4 interaction partially blocks the homing of progenitor/stem cells to the ischemic myocardium. 18 Thus, it has been well accepted that the SDF-1␣/CXCR4 axis plays a critical role in guiding the trafficking of EPC, though the exact mechanism(s) remained unknown, until the work presented herein. We reasoned that since SDF-1␣ itself is a soluble factor, even if it binds to CXCR4 on the surface of the circulating EPC, it would be unable to directly mediate attachment of EPC to the EC monolayer lining the blood vessel lumen within the microvasculature of a wound. Thus, under the shear force of the blood flow, circulating EPC would be unlikely to adhere to the EC monolayer. In this study, we hypoth-esized that direct cell-cell interactions are required between the EC lining the capillaries and the circulating EPC to achieve EPC homing to the target tissues, and that the effect of SDF-1␣ on EPC homing is mediated, at least partially, by regulating specific adhesion molecule(s) on EC monolayers. We aimed to identify such an adhesion molecule(s), which could mediate SDF-1␣-induced homing of EPC. We demonstrated that SDF-1␣ specifically upregulates the expression of E-selectin in murine and human mature EC monolayers. E-selectin is responsible for mediating the effect of SDF-1␣ on EPC homing by enhancing adhesion of EPC to EC monolayers and their transendothelial migration. Importantly, these effects result in significant enhancement of wound neovascularization and wound healing.
MATERIALS AND METHODS

Cells
Human microvascular endothelial cells (HMVEC), kindly provided by Dr. D. Fraker, University of Pennsylvania, Philadelphia, PA, were isolated from normal human dermis and cultured as described 19 on plates coated with 1% gelatin. Human EPC were purchased from the National Disease Research Institute, Philadelphia, PA, and cultured in complete endothelial growth medium 2 (EGM2) medium containing supplements and 5% fetal bovine serum (FBS) (Cambrex Bioscience, Walkersville, MD). The cells 293, 293T, and NIH/3T3 were cultured in Dulbecco's modified eagle medium (Invitrogen, Carlsbad, CA) and supplemented with 10% FBS. All cells were incubated at 37°C in 98% humidified air containing 5% CO 2 . For cell adhesion and transendothelial migration assays, EPC were labeled with Dil-Ac-low-density lipoprotein (LDL) (BT-902, Biomedical Technologies, Stoughton, MA) for 4 hours at 37°C, and washed with phosphate-buffered saline (PBS). Subconfluent HMVEC or EPC were stimulated with recombinant human SDF-1␣ (100 ng/mL) for various times as indicated in the experiments. Bovine serum Albumin (BSA) (100 ng/mL) was used as control.
Mice
All procedures were done with approval from the University of Miami Institutional Animal Care and Use Committee. Wild-type (WT) female C57 BL6 mice at 8 to 12 weeks of age were purchased from Charles River (Wilmington, MA). From the Jackson Laboratory (Bar Harbor, ME), 10-to 12-week-old NOD (NOD/shilTJ), 8-week-old E-sel Ϫ/Ϫ (B6.129S4-sele tmiDmil/J ) mice, and 10-to 12week-old Rosa26 (lacZ ϩ ) (B6.129S7-GT (ROSA)26sor/J) mice were purchased. For all surgical procedures, mice were anesthetized with an intraperitoneal injection of 80 mg/kg of ketamine and 20 mg/kg xylazine. For bone marrow transplantation experiments, 1 ϫ 10 7 bone marrow cells from Rosa26 mice were suspended in 100 L of PBS and transplanted into E-sel Ϫ/Ϫ or WT mice (C57 BL6) through tail vein injection.
Induction of Diabetes Plus Generation of Peripheral Cutaneous Wounds
Streptozotocin(STZ, Sigma-Aldrich) diabetes was induced and monitored as previously described. 16 NOD mice usually developed diabetes within 14 to 20 weeks. A total of 48 diabetic mice (N ϭ 28, STZ-C57; N ϭ 20, NOD) were studied. Serum glucose was measured from the mouse tail vein using a glucometer. Once serum glucose reached 250 mg/dL, mice were followed with daily measurements for 3 days prior to use in experiments. Mean serum glucose levels in diabetic mice were 446 mg/dL with a range of 356 to 512 mg/dL, whereas mean serum glucose levels in control nondiabetic mice were 122 mg/dL with a range of 96 to 137 mg/dL. Wounds were induced on the dorsal surface of the mouse back using a 6-mm punch biopsy. Full-thickness skin was removed, exposing the underlying muscle.
Recombinant Lentiviruses and Adeno-Associated Viruses
Based on prior studies documenting optimal viral transduction efficiency and on projected potential clinical relevance, 20 we selected lentivirus vectors for in vitro studies and adeno-associated virus (AAV) vectors for in vivo experiments, as tools for manipulating levels of SDF-1␣. Human SDF-1␣/lenti was constructed by inserting the human or murine SDF-1␣ genes into pHX vector. 21 Control vector, green fluorescent protein (GFP)/lenti was constructed as described previously. 22 Production of pseudotyped lentivirus was achieved by cotransfecting 293 T cells with 3 plasmids as described. 23 The lentiviruses collected 48 hours post-transfection displayed titers of around 10 7 transducing units/mL in NIH/3T3 cells. To infect target cells by lentiviruses, cells were exposed for 6 hours to virus with multiplicity of infection 5 in the presence of 4 g/mL polybrene (Sigma-Aldrich). Cells were then washed, cultured with regular complete medium for 2 additional days, and analyzed for protein expression by enzyme-linked immunosorbent assay(ELISA) or pooled for subsequent analysis as indicated in individual experiments. Murine SDF-1␣/AAV and control vector, LacZ/AAV were constructed by inserting the murine SDF-1␣ or LacZ gene into AAV2 vector. 24 Production of AAV was achieved by transfecting 293 cells with 3 plasmids, and AAV was purified by heparin chromatography method and titrated as previously described. 25 For local wound injections with recombinant AAV, 100 L of AAV at 10 12 viral unit/mL in PBS was injected into the wound base. For cell-based therapy, bone marrow-derived fibroblasts (BMDFs) were created by culturing murine bone marrow cells on plastic dish in Dulbecco's modified eagle medium supplemented with 10% FBS for 2 weeks with medium changes every 3 days. Adherent cells displayed spindle shape and are ␣-smooth muscle actin ϩ (data not shown) consistent with the myofibroblast phenotype. BMDFs were transduced with lentiviral vectors encoding murine SDF-1␣ or GFP (as control). Expression of exogenous mSDF-1␣ in BMDFs was confirmed by ELISA ( Fig. 1 , Supplemental Digital Content 1, online only, available at: http://links.lww.com/SLA/A87). A 6-mm punch biopsy skin wounds were created and 1 ϫ 10 7 mSDF-1␣/BMDFs versus GFP/ BMDFs suspended in 100 L of PBS were injected into the wound.
Polymerase Chain Reaction Array
The human adhesion molecules and extracellular matrix (ECM) RT 2 Profiler polymerase chain reaction(PCR) Array quantitatively profiles the expression of 84 genes of adhesion molecules and ECM (PA-011, SABiosciences, Frederick, MD). Subconfluent HMVEC were stimulated with recombinant human SDF-1␣ protein versus BSA at 100 ng/mL for 4 hours. Cells were harvested and total RNA was extracted from cells using Trizol (Invitrogen), and cDNA was synthesized using RT 2 First Strand Kits (SABiosciences). PCR array was carried out according to the manufacturer's protocol. The threshold cycle values were used to plot a standard curve. All samples were normalized to the relative levels of ␤-actin, and results are expressed as fluorescence intensity in relative levels.
BSA at 100 ng/m for 8 hours. Subsequently, culture medium was replaced with SDF-1␣-free EGM2 medium. 1 ϫ 10 5 Dil-Ac-LDLlabeled EPC, which were prelabeled and cultured on 2% agarosecoated plate as suspension for 16 hours, were added into wells and cocultured with the HMVEC monolayer for 1 hour at 37°C. Unbound EPC were washed out by PBS twice and adherent Dil-Ac-LDL-labeled EPC were measured by fluorescence scanner (GE Typhoon Trio, Piscataway, NJ) and photographed.
Cell Transendothelial Migration Assay
The HMVEC of 1 ϫ 10 4 cells/well were cultured in the upper chamber of a fibronectin (5 g/mL)-coated 24-transwell insert (8.0-M pores; Falcon 353097, Becton Dickinson Bedford, MA). Before each experiment, monolayer confluency was confirmed by inverted fluorescence microscopy. The HMVEC monolayers were stimulated with recombinant human SDF-1␣ or BSA at 100 ng/mL for 8 hours. Dil-Ac-LDL-labeled EPC of 1 ϫ 10 4 , which were prelabeled as detailed above, were added into the upper chamber in 0.3 mL basal EGM2 medium. Complete EGM2 medium of 0.6 mL was added to the lower chamber of the transwell. Cells were cultured for 12 hours at 37°C, and EPC traversing from the upper to the lower chamber of the transwell were quantified.
Immunoblotting, Immunostaining, and Immunohistochemistry
Immunoblotting was performed as described. 26 Membranes were probed with antibodies (Abs) to E-selectin (ab-18981) or ␤-actin (AC-15, Abcam, Cambridge, MA). This was followed by probing with horseradish peroxidase-conjugated secondary Ab (Santa Cruz, CA) and subjected to enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ). Membranes were stripped and reblotted as required in the individual experiments.
For immunostaining and immunohistochemistry (IHC), 5-m paraffin or frozen sections were processed as described, 21 and were then incubated with fluorescein isothiocyanate-anti-E-selectin (R&D Systems), PE-anti-kinase insert domain containing receptor (Cell Signaling Technology, Danvers, MA), or anti-SDF-1␣ (sc28876, Santa Cruz) for overnight at 4°C, then incubated with horseradish peroxidase-conjugated secondary antibodies. Immunoreactivity was detected using 3-3Ј-diaminobenzidine kit (Dako, Carpinteria, CA). The nuclei were counterstained with either 4Ј6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA) or hematoxylin (IHC). Negative controls for all antibodies were made by replacing the primary antibodies with nonimmunogen, isotype matched Abs from the same manufacturer.
Induction of Hindlimb Ischemia Plus Generation of Peripheral Cutaneous Wounds
To induce limb ischemia, the full length (about 3-4 mm) of the right femoral artery/vein vascular bundle was ligated and excised (following 2 groups of mice were studied: E-sel Ϫ/Ϫ mice ͓n ϭ 6͔ and WT mice ͓n ϭ 6͔). The skin was then closed with 5-0 nylon (Ethicon). Limb ischemia was confirmed by Laser Doppler perfusion imaging (LDI). Ischemic hindlimb wounds were induced on the ventral surface of the thigh of the mouse using a 4-mm punch FIGURE 1. SDF-1␣-engineered BMDFs promote neovascularization and diabetic wound healing. A, Left: wound healing rate expressed as percent recovery. Two groups of NOD mice were wounded and treated with mSDF-1␣/BMDFs versus GFP/BM-DFs. The fraction of initial wound area was measured daily by digital photography and ImageJ analysis until wounds were healed. Diabetic mice treated with mSDF-1␣/BMDFs had significantly improved wound closure rates from day 3 when compared with GFP/BMDFs treated controls. Right: representative wounds at different days are shown for each group. B, Wound blood vessel perfusion with Dil dye. Upper: representative images of Dil-stained wound blood vessels measured by laser scanning confocal microscopy at day 5 are shown for each group. Lower: Quantification of vessel density in the wounds. Percentage of threshold area covers all vessels detected as a percent of the entire wound area. mSDF-1␣/BMDFs treated wounds had significantly higher vessel density compared with the control. Data are presented as mean Ϯ SD of 4 wounds in each group. C, IHC of wound tissues injected with mSDF-1␣/BMDFs versus GFP/BMDFs for the detection of mSDF-1␣. Stronger mSDF-1␣ expression (brown) was observed in mSDF-1␣/BMDFs-treated wounds compared with the GFP/BMDFs treated wounds (40ϫ).
Annals of Surgery • Volume 252, Number 4, October 2010
E-selectin in Neovascularization biopsy. A full thickness section of skin was removed, exposing the underlying muscle distal to the level of the femoral fold. Recombinant murine SDF-1␣ protein (R&D Systems) was reconstituted in PBS and injected into the wound base (25 g/kg) right after the surgery.
Assessment of Wound Closure Rate
Wounds were followed serially with daily digital photographs using an Olympus digital camera. A ruler was included in all photos to allow for calibration of measurements. Images were analyzed using ImageJ software (Imaging Processing and Analysis in Java, National Institutes of Health, MD). Wound area was measured each day, and the wound's percent recovery rate was expressed as ͓(original wound area minus daily wound area)/(original wound area)͔ ϫ 100.
Blood Vessel Perfusion and Laser Scanning Confocal Microscopy
Mouse blood vessels were directly labeled in vivo in anesthetized mice by live perfusion using a specially formulated aqueous solution (7 mL/mouse) containing DiI (D-282, Invitrogen/Molecular Probes), which incorporates into EC membranes on contact, and was administered via direct intracardiac injection prior to animal sacrifice as previously reported. 27 Seven mL of fixative (4% paraformaldehyde) was injected following Dil perfusion, and the entire wound tissue was harvested. The vascular network was visualized by scanning the entire wound tissue to a thickness or depth of 200 m, using laser scanning confocal microscopy (Vibratome (VT1000S, Leica Microsystems). Vessel density was quantified assessing total number of red Dil-labeled vessels normalized to the entire scanned wound area, using ImageJ software.
Laser Doppler Perfusion Imaging
Limb perfusion was assessed daily using LDI (Periscan PIM II, Perimed AB, Sweden). The limb was defined as all imaged tissue distal to the femoral fold of the mouse. LDI was performed in a temperature controlled facility with weight-based sedation to minimize artifacts because of temperature fluctuations and level of sedation. Relative perfusion data were expressed as the ratio of the ischemic (right) to normal (left) limb blood flow.
Bone Marrow Transplantation and ␤-Galactosidase Assay for Tissue-Level Detection of Bone Marrow-Derived EPC
From 10-to 12-week-old Rosa26 (LacZ ϩ ) mice, 1 ϫ 10 7 bone marrow cells were engrafted into E-sel Ϫ/Ϫ mice (n ϭ 6) and WT mice (n ϭ 6) through tail vein injection right after creation of ischemic hindlimb wounds (right limb). The number of LacZ ϩ EPC recruited to wound tissues and integrated into blood vessels in tissue sections were quantified by ␤-galactosidase assay. Harvested wound tissues were frozen and tissue sections were then incubated with X-gal (Fermentas, Canada) and anti-KDR (ab-2349, Abcam) for 2 hours at room temperature. Sections were counterstained with nuclear fast red (Vector Laboratories). The number of EPC was quantified by counting ␤-galactosidase ϩ cells in KDR ϩ vessels in serial sections of wound granulation tissues underlying the excisional wounds at postoperative day 7 (n ϭ 3) in 5 random high power fields (HPF, 40ϫ) per section in at least 3 serial sections.
Statistical Analyses
Statistical analysis of differences was performed using analysis of variance and 2-tail Student t test. Data were analyzed using Microsoft Excel (Microsoft Corp, Redmond, WA). Data are expressed as mean Ϯ standard error. Values are considered statistically significant when P Ͻ 0.05.
RESULTS
SDF-1␣-Engineered Cell-Based Therapy Promotes Cutaneous Wound Neovascularization and Diabetic Wound Healing
We previously reported that tissue levels of SDF-1␣ in diabetic murine wounds were significantly decreased, partly because of its down-regulation in myofibroblasts. 16 In this study, we sought to test efficacy of SDF-1␣-engineered cell-based therapy for diabetic wound healing. The purpose is to test the pro-healing effect of fibroblast-derived SDF-1␣ on diabetic wound healing in a genetic (NOD) diabetes murine model. BMDFs were selected, as mature resident cutaneous fibroblasts in patients with diabetes associated wounds are known to be impaired, and thus carry little clinical relevance as potential therapeutic vehicle. Diabetic wounds treated with mSDF-1␣/BMDFs were completely healed significantly faster than those injected with GFP/BMDFs (Fig. 1A) . Similar pro-healing results were observed in STZ-C57 diabetic mice with cutaneous wounds (data not shown). The naked vector treatment of wounds also showed a pro-healing response but not as pronounced as with the cell-based approach (Fig. 2 , Supplemental Digital Content 2, online only, available at: http://links.lww.com/SLA/A88). The most significant difference was observed at day 4 and 5. Correspondingly, significantly more active neovascularization developed in wounds treated with mSDF-1␣/BMDFs compared with the control wounds as demonstrated by confocal laser scanning microscopy of wounds after blood vessel perfusion with Dil dye (Fig. 1B) . Wounds were harvested and subjected to IHC analysis. Stronger expression of SDF-1␣ in wounds injected with mSDF-1␣/BMDFs versus GFP/BMDFs was confirmed by IHC (Fig. 1C ). These results confirmed pro-healing and proangiogenic effects of SDF-1␣ in diabetic murine models and provided preclinical evidence that SDF-1␣-engineered cell-based therapy may serve as a novel tool for the treatment of diabetic wounds.
FIGURE 2.
Increased adhesion of EPC to SDF-1␣-stimulated EC monolayer in vitro. Dil-Ac-LDL-labeled EPC were added to EC monolayers, which were stimulated with SDF-1␣ or BSA. After 30 minutes, unbound EPC were washed out. Bound EPC were quantified by fluorescence scanning. A, Representative images. B, Quantitative data. Data are presented as mean Ϯ SD of 3 independent assays in which samples were duplicated.
Enhanced Adhesion of Human EPC to SDF-1␣-Stimulated EC Monolayer in vitro
To test our hypothesis that the effect of SDF-1␣ on EPC homing is mediated by regulating adhesion molecule(s) on mature EC, we first examined whether SDF-1␣ stimulation could make an EC monolayer more likely to support adhesion of EPC in an in vitro cell-cell adhesion assay. Subconfluent HMVEC were stimulated with recombinant human SDF-1␣ or BSA. Dil-Ac-LDL-labeled EPC were added into wells and cocultured with EC-monolayer. Unbound EPC were washed out and adherent Dil-Ac-LDL-labeled EPC were measured by fluorescence scanner ( Fig. 2A ). There was approximately an 8-fold increase in the number of EPC adherent to the SDF-1␣-stimulated EC monolayers compared with BSA-treated control (Fig. 2B) . These data indicated that SDF-1␣ stimulation promotes direct EPC-EC adhesion, suggesting that the expression of certain adhesion molecule(s) on EC may be specifically regulated by SDF-1␣.
SDF-1␣ Stimulation Upregulates Expression of E-selectin in EC Monolayers (In Vitro) and Wound Capillary Endothelium of Mice (In Vivo)
To identify the adhesion molecule(s) upregulated by SDF-1␣ in EC monolayers, we carried out RT 2 Profiler PCR array. Of the 84 genes tested in the array, 13 were upregulated (Ͼ1.5-fold), whereas 20 down-regulated (Ͻ1.5-fold), and 51 were unaltered (Table 1) . Notably, the expression of E-selectin gene was increased about 2.3-fold on SDF-1␣ stimulation (Fig. 3A) . To validate the observed upregulation of mRNA of E-selectin, we conducted immunoblotting analyses and confirmed an upregulated protein expression of E-selectin in SDF-1␣-stimulated compared with BSA-treated EC monolayers (Fig. 3B) . To further validate the upregulation of E-selectin by SDF-1␣ in mature EC in vivo, we examined vessels in diabetic NOD mice wounds injected with mSDF-1␣/AAV versus lacZ/AAV by immunostaining. EC of blood vessels in diabetic murine wounds injected with mSDF-1␣/AAV expressed stronger E-selectin compared with those injected with LacZ/AAV (Fig. 3C ). Increased tissue levels in mSDF-1␣/AAV was demonstrated by IHC ( Fig. 3D) . These experiments identified E-selectin as one key adhesion molecule that is upregulated as a down-stream target of SDF-1␣ in vascular EC.
Upregulated E-selectin Is Responsible for Mediating SDF-1␣-Enhanced EC-EPC Interaction and EPC Transendothelial Migration
To study whether upregulated E-selectin is responsible for mediating SDF-1␣-enhanced EC-EPC adhesion, we tested the effect of E-selectin antagonist on EPC adhesion to SDF-1␣-stimulated EC monolayer in vitro. Subconfluent HMVEC stimulated with recombinant human SDF-1␣ or BSA was cultured with SDF-1␣-free EGM2 medium containing either E-selectin neutralizing Ab or isotype-matched control Ab (2 g/mL) and incubated for 15 minutes at 37°C before adding EPC. Subsequently, Dil-Ac-LDL-labeled EPC were added into the wells and co-cultured with the ECmonolayer. Unbound EPC were washed out, and adherent Dil-Ac-LDL-labeled EPC were measured by fluorescence scanner. The addition of E-selectin neutralizing Ab significantly inhibited the number of EPC adherent to SDF-1␣-stimulated EC monolayers, whereas control Ab had no significant effect (Fig. 4A) . To further investigate the biologic function of E-selectin in mediating a specific interaction between EPC and the EC monolayer, we tested whether increased adhesion between EPC and the EC monolayer results in more EPC transmigrating through the EC monolayers, and if yes, whether this transmigration effect is E-selectin-dependent. EPC transendothelial migration was tested in an in vitro transwell system. HMVEC monolayers were cultured in the upper chamber of transwell inserts in the presence of ␥hSDF-1␣ or BSA. Fifteen minutes prior to adding EPC into the insert, EGM2 medium in the lower chamber was replaced with fresh medium containing ␥hSDF-1␣ or BSA, respectively. Dil-Ac-LDL-labeled EPC suspension was added into the insert and cultured for overnight. Compared with BSA-treated EC monolayers, SDF-1␣-stimulated EC monolayers showed significantly increased EPC transmigration from the upper to the lower transwell chamber (Fig. 4B) . Importantly, this effect is, at least partially, E-selectin-dependent, because blockade of E-selectin by adding neutralizing Ab (2 g/mL) to the transwell was able to significantly inhibit EPC transendothelial migration (Fig.  4B) . Overall, these results demonstrated that upregulated E-selectin is responsible for mediating SDF-1␣-enhanced EC-EPC adhesion and EPC transendothelial migration. 
SDF-1␣ Stimulation Upregulates Expression of E-selectin Ligands in EPC
Ultimately, the direct interaction between EC lining the wound's capillaries and the circulating EPC would depend on mutually relevant counterparts of adhesion molecules on the surface of both cell types. We hypothesized that SDF-1␣ might induce expression of relevant adhesion molecule(s) on both EC and EPC. Based on the results detailed above that SDF-1␣-induced E-selectin on EC mediates direct EC-EPC interactions, we specifically examined the expression of 2 E-selectin ligands, CD44, and CD162 (P-selectin glycoprotein-1), on EPC in response to SDF-1␣ stimulation. Subconfluent human EPC were stimulated with ␥hSDF-1␣ or BSA, respectively, for various periods of time. Cells were harvested and subjected to immunoblotting analyses. Unstimulated EPC expressed strong basal levels of CD162 and low levels of CD44. SDF-1␣ stimulation upregulated expression of both CD162 and CD44 in EPC (Fig. 5 ). Induction of CD162 and CD44 was first observed in 4 hours on SDF-1␣ stimulation and continued to increase until 16 hours. These experiments confirmed that EPC express basal levels of E-selectin ligands and show that SDF-1␣ is able to upregulate the expression of these E-selectin ligands in EPC, consistent with the overall hypothesis that the soluble factor, SDF-1␣, mediates EPC homing effects by specifically regulating the profile of adhesion molecules on these 2 key cell types, the mature EC and the EPC.
E-selectin Is Required for Mediating Effects of SDF-1␣ on EPC Homing, Neovascularization and Wound Healing in Murine Ischemic Hindlimb and Cutaneous Wound Model
To study the specific biological importance of SDF-1␣induced E-selectin in EPC homing, neovascularization, and cutaneous wound healing, we employed a loss-of-function approach in combination with bone marrow transplantation. A murine model of unilateral hindlimb ischemia via femoral ligation/excision and subsequent bilateral 4-mm cutaneous excisional wounding was created in E-sel Ϫ/Ϫ versus WT mice. Recombinant murine SDF-1␣ was administrated to wounds via direct wound injections. Further treatment was provided by engrafting bone marrow cells from Rosa26(LacZ ϩ ) mice into mice via the tail vein, to quantify (partially) the contribution of EPC homing to neovascularization and wound healing. LDI was used to confirm postoperative limb ischemia, and monitor and quantify the spontaneous restoration of hindlimb blood flow via mean perfusion measured over time. Daily wound area measurements were obtained by digital photography. Neovascularization in wound tissues was evaluated by blood vessel Dil perfusion and subsequent laser scanning confocal microscopy in harvested wound tissues in half of experimental mice at day 7. In the remaining mice, the wounds were harvested and subjected to IHC. EPC recruited to wound tissues and incorporated into blood vessels were detected by double staining with ␤-gal (blue) and anti-KDR. Compared with WT mice, ischemic hindlimbs in E-sel Ϫ/Ϫ mice showed delayed improvements in perfusion over time as indicated by the significantly lower mean flux measurements (Fig. 6A) . Consistently, ischemic wounds in E-sel Ϫ/Ϫ mice had significantly slower closure rate that in WT mice (Fig. 6B ). In addition, ischemic wounds in E-sel Ϫ/Ϫ mice were much more poorly vascularized compared with those in WT mice (Fig. 6C) . The poor neovascularization in ischemic wounds of E-sel Ϫ/Ϫ mice was, at least partially, related to fewer EPC homing, because significantly less LacZ ϩ cells were detected in blood vessels of ischemic wounds in the E-sel Ϫ/Ϫ mice compared with the WT mice (Fig. 6D) . These in vivo experiments demonstrated that E-selectin is required for mediating SDF-1␣-induced EPC homing, neovascularization, and wound healing.
DISCUSSION
In the present study, we have demonstrated that SDF-1␣ carries significant relevance as a potential new target to enhance diabetic wound healing and that the effect of SDF-1␣ on enhancing EPC homing, neovascularization, and wound healing is mediated by the upregulation of E-selectin expression on EC as well as the upregulation of corresponding E-selectin ligands on the EPC. Thus, E-selectin may be a potential new target in the unsolved epic problem of diabetes-associated cutaneous impaired wound healing. These data demonstrate that SDF-1␣ increases expression of E-selectin on the luminal surface of mature EC, and thereby creates a microenvironment that promotes adhesion and transendothelial migration of EPC. These effects, in turn, promote limb and wound neovascularization and enhance wound healing.
The microvasculature in the granulation tissue of cutaneous wounds is physically supported by connective tissue elements elaborated by resident fibroblasts. These fibroblasts provide a unique microenvironment that facilitates and sustains the newly formed vessels. Fibroblasts and their activated counterpart, the myofibroblasts, play a pivotal role in regulating neovascularization in the process of wound healing by synthesis of ECM and secreting various soluble factors. 28 -31 Myofibroblasts can either arise from the local, resident fibroblasts or from circulating mesenchymal precursors/stem cells. 32, 33 Recently, cell-based therapy has become a promising novel option to improve vascularization or tissue regeneration. 34 Using cell-based therapy, we have shown that engrafting SDF-1␣-engineered BMDFs into diabetic wounds, where tissue levels of SDF-1␣ are known to be down-regulated, 15 can significantly improve tissue levels of E-selectin on EC and promote wound neovascularization and wound healing in different murine diabetic wound models (STZ and NOD). Cell-based therapy showed improved healing effects, in our murine models, compared with gene therapy, suggesting that BMDFs can provide additional beneficial effects on wound healing. We had previously reported the contribution of EPC to enhanced neovascularization in an STZinduced murine diabetic wound model. 15 This most current work demonstrates that this effect of SDF-1␣ is also seen in NOD mice and is E-selectin-dependent, as less EPC recruitment along with poor neovascularization and poor wound healing occurred in the ischemic wounds of E-sel Ϫ/Ϫ mice compared with that in WT mice despite local wound administration of recombinant SDF-1␣ protein.
Our overall prior and current results implicate E-selectin as a target that could be modulated to enhance EPC-associated neovascularization and healing in diabetes associated wounds. E-selectin is only minimally expressed constitutively in the unstimulated/quiescent EC. Thus, the basal level of E-selectin expressed on the luminal surface of blood vessels is likely insufficient for circulating EPC to be captured in the "homing" process. Some proinflammatory cytokines, such as tumor necrosis factor-alphaand Interleu-FIGURE 5. SDF-1␣ induces expression of E-selectin ligands in EPC. EPC were stimulated by SDF-1␣ and cells were harvested at various time points. Expression of E-selectin ligands, CD162, and CD44, was examined by Western blotting assay. ␤-actin was used as loading control. Experiments were repeated twice.
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E-selectin in Neovascularization kin-1, can induce vascular expression of E-selectin. 35 For example, E-selectin is known to be involved in the interaction of leukocytes and the EC lining of blood vessels for leukocyte transendothelial migration in inflammation. Our findings that E-selectin is required for EPC-EC interaction in postnatal EPC-mediated neovascularization support the novel hypothesis that EPC may use adhesion molecules for their homing to sites of damaged tissues similar to the adhesion molecules engaged by leukocyte recruitment to sites of inflammation. 36, 37 It appears rational that sharing common adhesion molecules for both EPC and leukocyte homing is resource efficient for the body, and in fact, in many cases, inflammatory cells are recruited along with reparative progenitor cells to sites of damaged tissues wherein neovascularization as well as inflammatory cell-mediated mechanisms against contamination and infection are needed, although no obvious inflammation was noted in our experimental wounds. E-selectin is only one of several adhesion molecules that are upregulated by SDF-1␣ stimulation in vascular EC monolayers. In addition to E-selectin, several other adhesion molecules, such as vascular cell adhesion molecule-1 and integrin ␣4, were also induced. It is likely that more than one of these adhesion molecules is involved in orchestrating the dynamic process of EPC homing, which involves EPC rolling, firm adhesion to the EC monolayer, and subsequent transendothelial migration. Additionally, because EPC homing is a complex and dynamic process involving cell-cell and cell-ECM engagement and disengagement a spatiotemporal manner, it is not surprising that some adhesion molecules need to be downregulated. In fact, we observed that 20 genes were down-regulated by SDF-1␣ stimulation. In this study, we focused on E-selectin because it has also been previously reported to be involved in EPC homing to ischemic muscle. 38 Our study not only confirms the critical role of E-selectin in EPC homing from a novel perspective never previously realized (diabetes-associated cutaneous wounds), but also reveals for the first time that upregulated E-selectin mediates SDF-1␣-induced EPC homing. Given our prior findings on the FIGURE 6. Involvement of E-selectin in SDF-1␣-induced EPC homing, neovascularization, and wound healing in murine model of hindlimb ischemia plus cutaneous wounding. A, Upper: representative images of noninvasive LDI measurements showing spontaneous restoration of blood flow into ischemic hindlimbs after femoral artery ligation/excision in E-sel Ϫ/Ϫ versus WT mice. Lower: Quantitative data of LDI measurements. Ratio of ischemic versus normal hindlimb between 2 groups of mice at various time points. Data are presented as mean Ϯ SD from each group (n ϭ 6/group). B, Wound closure rates in E-sel Ϫ/Ϫ versus WT. Upper: representative images of wound healing in E-sel Ϫ/Ϫ and WT mice. Deletion of E-selectin delayed wound healing. Lower: Quantitative wound closure rates in E-sel Ϫ/Ϫ versus WT mice. Data are presented as percentage wound closure (recovery), mean Ϯ SD from each group (n ϭ 6/group). C, Wound blood vessel perfusion with Dil dye. Upper: representative images of Dil-stained wound blood vessels detected by confocal laser scanning photography at day 7 are shown for each group. Lower: Software-assisted quantification of vessel density in the entire area of residual wounds at day 7, as percent fluorescence. Wounds from WT mice had significantly higher vessel density compared with that from E-sel Ϫ/Ϫ mice. Data are presented as mean Ϯ SD of 3 wounds in each group. D, E-sel is essential for EPC homing to the wound lesion. 1 ϫ 10 7 of bone marrow cells from ROSA26 (LacZ ϩ ) mice were transplanted to E-sel Ϫ/minus͔ and WT mice, respectively. Ischemic hindlimb wounds were created and SDF-1␣ was injected into wounds. Seven days after cell transplantation, wounds were harvested and frozen samples were subjected for X-gal (blue) and anti-KDR (brown) staining. Upper: representative images of double staining. Lower: number of double positive cells was counted from 5 randomly selected fields in wound samples. Data are percentage of mean Ϯ SD from each group (n ϭ 3 wounds/group).
connection between the diabetic phenotype and the cutaneous wound down-regulation of SDF-1␣, these novel data point to E-selectin as a new target in the field of diabetes impaired wound healing. The functional relevance of other listed adhesion molecules/ ECM requires further study.
There are 3 known ligands capable of interacting with E-selectin, and we examined 2 of them (CD162 and CD44). Similar to mature EC expressing low basal levels of E-selectin, the EPC express low basal levels of CD162 and CD44 as well. The significance of the detected low basal level expression of these adhesion molecules is unclear. Nevertheless, these low levels are likely insufficient to bring about significant EPC-EC interaction under unstimulated conditions. Interestingly, the 2 examined E-selectin ligands on EPC are responsive to SDF-1␣ stimulation. Thus, it is possible that SDF-1␣ produced in wounded tissue in response to hypoxia inducible factor-1 ␣ upregulation in the wound's relative hypoxic microenvironment 39 can stimulate both local EC and circulating EPC to express adhesion molecules and thereby enhance EPC-EC interactions that result in EPC homing. Our new proposed working model is that the circulating EPC get stimulated when they pass through the "swampy" low-flow vessels of the injured tissue wherein a specific profile of adhesion molecules are upregulated under the influence of SDF-1␣ that promotes the homing process. When these stimulated EPC come back to the site on recirculation, they are "captured" or become adherent to the "sticky" EC surface of the wound's capillary beginning the processes of transendothelial migration and EPC extravasation that are required for EPC homing. In this sequence of events, E-selectin may play a central role.
CONCLUSIONS
Our experiments demonstrated that SDF-1␣ specifically upregulates the expression of E-selectin in mature EC and E-selectin ligands on EPC, thereby mediating EC-EPC adhesion and EPC homing. These findings provide profound and novel insight into the molecular mechanism underlying the biologic effect of SDF-1␣ on EPC homing and point to E-selectin as a new potential target for therapeutic manipulation of EPC homing in diabetes-associated microangiopathy and delayed wound healing. The modulation of E-selectin and its ligands in EC and EPC may offer an opportunity to not only regulate the EPC-associated direct angiogenic response, but also, the associated direct and indirect effects on wound healing that are intrinsically relevant to the unsolved clinical problem of delayed diabetes-associated cutaneous wound healing. Our findings could be developed into a new translational platform for subsequent clinical trails. Successful completion of clinical testing may offer a novel paradigm for advancing and transforming the field of diabetic wound care, and eliminate the need for over 100,000 major limb amputations per year at a health care cost that exceeds 2 Billion dollars, yearly, in the United States alone.
Discussions
DR. MICHAEL T. WATKINS (BOSTON, MA): Drs. Liu, Valazquez, and the research team at the University of Miami presented the best combination of in vitro and in vivo work to suggest a novel experimental treatment for diabetic wounds and ischemic wounds. Previous seminal work from their laboratory demonstrated decreased expression of stromal-derived growth factor in patients with diabetes' wounds. To put that observation in perspective, one must know that stromal cell-derived factor (SDF)-1 is strongly chemotactive for lymphocytes and is thought to play a major role in neoplasia. During embryogenesis, SDF-1 is known to direct the migration of hematopoietic cells from fetal liver to bone marrow and modulate, in part, the development of large blood vessels.
Genetic deletion of the SDF-1 gene results in death before birth or within 1 hour of life. The finding that SDF is reduced in diabetic tissue, a startling revelation when first described by Drs. Liu and Velazquez, has been recently confirmed by other investigators.
In the work presented to us today, Drs. Liu and Velazquez used elegant in vitro and in vivo data to provide compelling evidence that administration of SDF growth factor into ischemic diabetic wounds using a cell-based therapy improved the rate of wound healing and it was associated with improved blood perfusion. These data are very convincing and contradict data published by other laboratories implicating a primary role for P-selectin in wound healing, relegating E-selectin to a primarily inflammatory and acute event.
Those authors, however, used in vivo and in vitro techniques in normal mice. This translationally relevant data used in diabetic and ischemic tissues deserve considerable attention. I have several questions.
First, in humans with advanced systemic atherosclerosis and diabetes, bone-marrow-derived endothelial progenitor cells (EPCs) are decreased in number and function as compared with healthy young individuals. Are the EPCs in these relatively young diabetic mice decreased or preserved as compared with those in diabetic or elderly humans?
Second, the microarray analysis presented was focused primarily on cells exposed to SDF in vitro. Because wound healing is such a complicated, multifaceted process, have you repeated these experiments using tissue from the wounds themselves subjected to cell therapy?
Third, chronic levels of oxidative stress and inflammation are thought to contribute to problems with wound healing in diabetic humans. Have you considered expanding your microarray analysis to include assessment of the expression of vascular endothelial growth factor (VEGF), VEGF receptors, IL-10, which is an anti-inflammatory cytokine, glutathione peroxidase, superoxide dismutase, or other antiinflammatory molecules that might influence wound healing?
Last, does SDF administration using cell-based lentiviral vectors result in a pharmacologic or physiologic expression of E-selectin in the tissue? How does the expression of E-selectin in SDF-treated mice compare with nontreated, nondiabetic mice? DR. K. CRAIG KENT (MADISON, WI): It seems that if you are able to transfer SDF-1 alpha to a wound in a diabetic patient that the wound might heal faster. The question is how do you get levels of SDF-1 alpha in a wound to increase? Do you directly apply the protein? Can you transfect the wound cells? Can you transfect fibroblasts and infuse fibroblasts into the wound? DR. ZHAO JUN LIU (MIAMI, FL): In answer to Dr. Watkins' first question, whether the percentage of the EPC decrease observed in mice is comparable to that observed in human diabetic patient or not. Based on published literature, the percentage of the EPC decrease in both type 1 and type 2 human diabetes patients was roughly 40% to 50%. We tested different types of diabetic mouse models including STZ induced diabetic mice, db/db mice, and NOD diabetic mice. In all these mice, there is some variation, but overall we saw a 30% to 50% down-regulation of the EPCs in the circulation.
Dr. Watkins second question asked whether we tested the diabetic wound instead of cells exposed to SDF-1, because diabetes is a complicated disease. We only tested the cells exposed to SDF-1. This is a very complicated process and it involves many kinds of soluble factors, not just SDF-1 alpha.
We have not tested the diabetic wound tissue, because the tissue contains different types of cells. Not just endothelial cells, but also fibroblasts, epithelial cells, and inflammatory cells.
Thus, data generated from this tissue may be difficult to interpret. We thought the best approach to address this question might be through the use of a laser capture dissection technique to isolate these endothelial cells from the diabetic wound tissue to perform the gene profile. Then, the information will be more valuable. So, we are planning to do this in the future.
Dr. Watkins third question asked about oxidative stress and inflammatory molecules potentially involved in diabetic wounds and whether we tested for them. The answer is no, because in this study we focused on the adhesion molecule and did not include any of the oxidative stress and inflammatory molecules. Certainly, we agree this is an important factor that we should take up in the future.
Dr. Watkins fourth question asked whether SDF-1 applied by a viral vector can reach the pharmacological or physiological level of E-selectin expression in the tissue, and whether we compared the expression of E-selectin in SDF treated mice to that of nontreated and nondiabetic mice. We clearly demonstrated that the injections of SDF-1 alpha into the diabetic wound can increase the tissue level of vascular expression of E-selectin compared with the control mice; both are diabetic wounds. We have not tested the nondiabetic and nontreated mice, but this will certainly be a very important question in judging the effectiveness of this treatment. We are planning to do this in the future. I thank Dr. Kent for his important question. In terms of the potential approach to increasing the tissue level of SDF expression, we tested directly injecting recombinant soluble protein, and injecting this adeno-associated viral vector. Adeno-associated virus is a safe type of viral vector that goes to clinical trial at this moment. Also, we can use this cell-based approach as we test the uses of SDF-1 engineered fibroblast. All these methods can be used to raise the tissue level of SDF-1 alpha.
